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Gentamicin is a broad-spectrum antibiotic which belongs to the 
aminoglycoside group of antibiotics. It was first studied and described 
by Heinstein and co-workersl in 1963, and was then isolated, purified 
and characterized by Rosselot and colleagues2 in 1964. Although newer 
members of the aminoglycoside antibiotics (e.g. tobramycin, amikacin, 
netilmicin and sisomycin) are now available, gentamicin remains the 
first line agent in the armamentarium against gram-negative bacterial 
infections. 
Like other aminoglycoside antibiotics, gentamicin is rapidly 
bactericidal, it can be actively transported across the cell membrane 
and irreversibly bound to the bacterial ribosome, wheYe it inhibits 
protein synthesis and decreases the fidelity of translation of the 
genetic codes. Hhile limited in its action against most gram-positive 
bacteria, its antibacterial activity is primarily directed against 
aerobic, gram-negative bacilli. It has little activity against 
anaerobic microorganisms or facultative bacteria under anaerobic 
conditions. 
Due to the highly polar cationic structure of gentamicin, it is 
very poorly absorbed from the gastrointestinal tract, but is completely 
absorbed after intravenous and intramuscular injection v:ith the :nost 
common route being intermittent intravenous infusion. 
l 
Since gentamicin is water-soluble, it rapidly distributes into the 
extracellular fluid compartment. Because of its polar nature, 
gentamicin is largely excluded from the intracellular space; thus 
concentrations are low in most tissues and secretions. High 
concentrations can only be found in the renal cortex and in the 
endolymph and perilymph of the inner ear. This pattern of distribution 
presumably accounts for the nephrotoxicity and ototoxicity of 
gentamicin. Concentrations in the cerebral spinal fluid are also low, 
therefore intrathecal or intraventricular administration is necessary in 
cases of gram-negative bacillary central nervous system infections. 
There is negligible binding of gentamicin to plasma protein,3 
Due to active hepatic secretion, the concentrations of gentamicin 
in the bile approach 30% of concomitant plasma concentrations; this 
represents a very minor excretory route. Gentaffiicin is excreted almost 
entirely by glomerular filtration, the renal clearance parallels the 
creatinine clearance and it may take as long as thirty days for complete 
recovery in urine. The plasma half-life is about two to three hours in 
patients with normal renal functions except for neonates. Since the 
pharmacokinetic parameters have a wide inter-individual variation, serum 
concentration determinations are essential for individual therapy to 
ensure the optimal use of this agent. Gentamicin is removed by 
hemodialysis as well as peritoneal dialysis, A supplemental dose 
therefore should be given after dialysis and frequent monitoring of 
concentrations in the plasma is important. 
2 
Although used for almost two decades, the factors associated with 
good clinical outcome and nephrotoxicity in patients receiving 
gentamicin therapy have not been definitively identified. 
\ihen gentamicin was first used, infective organisms were thought 
to influence the clinical outcome significantly.4-6 Cox, et al.4 found 
the bacterial eradication rate for Pseudomonas urinary tract infections 
(UTI's) was less than non-pseudomonal UTI's (74.2% vs. 97 .1%, p<O.OS). 
ShimizuS in a report of clinical experiences with gentamicin in Japan, 
also found that Pseudomonas and Proteus infections were cured less often 
than infections due to other microbes. Bodey, et al. 6 however found 
that Pseudomonas was not associated with a lower cure rate when compared 
with other microorganisms in cancer patients. Several other reports 
have similar results. 7-11 Bodey, et al. also found that infections due 
to Proteus species and Klebsiella-Enterobacter had a higher response 
rate (100% and 90%, respectively) when compared with other infections. 
Site of infections has been identified as a factor influencing 
clinical outcome. Respiratory and biliary tract infections were found 
to have lower response rates than other infections by ShimizuS (p<O.OS). 
Respiratory tract infections alone, however, did not show significant 
differences in terms of cure rates. Other investigators also found that 
pneumonias did not show significantly lower response rates.6, 7,13 
UTI's, on the other hand, were shown to have a higher cure rate than 
3 
other infections in several different studies, 6 • 7 • 9 In addition, Bodey, 
et a1.6, 7 found that cellulitis appeared to have a better cure rate as 
compared to other infections (p<O.OS). 
The relationship between the gentamicin serum concentrations and 
clinical response has also been studied. Jackson and Riff 12 reported 
that the persistence of pseudomonal bacteremia was inversely related to 
serum concentration. Seven of eight patients with peak concentrations 
of 2 mcg/ml or less had persistent bacteremia, whereas all six 
non-leukemic patients with peak concentrations of 4 mcg/ml or more had 
their bacteremic state eliminated ( p<O. OS). Noone, et al.lS in the 
investigation of gentamicin therapy in gram-negative infections also 
reported that for UTI's, patients with peaks of S mcg/ml or more had a 
higher cure rate ( 17 of 18 or 94%) than patients with peak less than S 
mcg/ml (0 of 2 or 0%) (p<O.OS). For the 1S episodes of wound infection, 
12 were cured and a peak of S mcg/m1 or more was achieved in all 1S 
episodes. For septicemia, 10 of 11 patients (91%) with peak of S mcg/ml 
or more were cured when compared to the 0% cure rate in the four 
patients with lower peak concentrations (p<0.01 ). For pneumonia 
patients, peak concentrations of 8 mcg/m1 or more were achieved in 18 
patients, of these 16 (89%) were cured; of the seven pneumonia patients 
whose peak concentrations were less than 8 mcg/m1, only three (43%) were 
cured (P<O. OS). Noxe, et a1.16 in a recent study of the association of 
aminog1ycoside levels with mortality from gram-negative bacteremia 
showed that only one death (2.4%) occurred in 41 patients with initial 
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peak concentrations of greater than 5 mcg/ml of gentamicin or tobramycin 
and greater than 20 mcg/ml of amikacin as compared to the 20.9% 
mortality in the 43 patients •·ith lower initial peak concentrations 
(p<O. 01). \>/hen mean peak serum concentrations were compared, five 
deaths (8.3%) occurred in 60 patients with mean peak concentrations of 
greater than 5 mcg/ml of gentamicin or tobramycin and >20 mcg/ml of 
amikacin; and five deaths ( 20. 8%) occurred in 24 patients with lower 
concentrations; this result was not statistically significant (p>O .1). 
Six deaths (13.0%) occurred in the 47 patients with initial trough 
aminoglycoside levels of greater than 2 mcg/ml of gentamicin and 
tobramycin, and of greater than 8 mcg/ml of amikacin; four deaths 
(11.0%) occurred in the 36 patients with lower trough levels, there was 
no significant association between initial trough levels and subsequent 
patient sur vi val (p>O .1). On the other hand, other investigators found 
no correlation between serum concentrations and the clinical outcome in 
their patient populations with their serum concentrations less well 
defined.l0,17,18 
Minimal inhibitory concentrations (MIC' s) of the pathogens have 
also been associated with clinical outcome. Athlin, et al.lO stated 
that there was a positive correlation between low MIC and clinical 
improvement although the number of isolates were very small (seven 
isolated strains). Klastersky, et al. 8 found that of 101 patients •,Jith 
infections due to organisms that were inhibited by a concentration of 3 
mcg/ml or less of antibiotics, 66 (65%) responded to therapy, 
5 
whereas only 23 of 42 (55;;) infections caused by more resistant bacteria 
were cured, this difference, however, was not statistically significant 
(p>0.1). In a study of amikacin, \·lilliams, et al.19 found that the mean 
l.:IC was significantly higher in the patients "·ho were not cured than in 
patients who were cured (8.8 + 1.8 vs. 3.3 + 0.3 mcg/ml, p<O.OS). 
Parry, et al., 13 on the other hand, stated that response was not related 
to pretreatment MIC's in patients receiving gentamicin and 
carbenicillin. 
Serum antibacterial titer has also been studied8 and correlated 
with clinical outcome. It was 
serum bacteriostatic titer ,.;as 
observed that of the 73 patients whose 
equal to or greater than 1:8, 56 (77%) 
responded to their antibiotic therapy, while only 33 ( 47~;) of the 70 
patients whose inhibitory titer was lower responded (p<O .01). The mean 
antibacterial activity in the urine of patients who wer-e cored of 
urinary tract infections was also much higher than patients who \vere not 
cured (mean bateriostatic titer, 1:16 vs. 1:2; mean bactericidal titer 
1:8 vs. 1:2); though no statistical test was performed. Reyr:::ann, 
et al., 20 however, showed that a mortality of 32% (l6 of 50) was found 
among those with a serum inhibitory level of less than 1:8 and a 
mortality of 37% (16 of 43) was found among those wHh an inhibitory 
level of 1:8 or more, this defference was not statistically significant 
(p>O.S). 
There are discrepancies between the anticipated clinical response 
6 
rates and the ability of an antibiotic to inhibit bacterial growth. 
This may be partially explained by antibiotic synergism. Concomitant 
antibiotics therefore may be a factor positively correlated with 
clinical cure. 
Bodey, et al. 6 • 7 in their studies of gentamicin treatment in 
cancer patients showed that initial neutrophil counts significantly 
influence the clinical cure rate. The response rate of gram-negative 
bacilli infections increased from 31% to 62% to 83% as the initial 
neutrophil counts increased from less than iOO to 101-1000 to greater 
than 1000 /rnm3 (p<O .01). 
Parry, et al.13 observed that the severity of underlying diseases, 
namely, nonfatal, ultimately fatal, and rapidly fatal according to the 
criteria set up by McCabe and Jackson21 was related to the clinical 
oiJtcome during gentamicin treatment. Twenty of twenty-one patients 
(95%) with nonfatal underlying diseases responded favorably to either 
tobramycin-ticarcillin or gentamicin--carbenicillin regimen, compared to 
29 of 31, of patients (85%) with ultimately fatal and 18 of 27 patients 
(67%) with rapidly fatal underlying diseases (p<O.OS). 
investigating the relationship of severity of underlying diseases \·:ith 
the mortality in patients with gram-negative bacteremia, Moore, et al.16 
found a mortality rate of 67% in patients \;ith rapidly fatal, 25% in 
patients with ultimately fatal and 8% in patients with nonfatal 
underlying diseases (p=O.Ol). 
7 
In terms of the toxicities induced by gentamicin, the incidence of 
nephrotoxicity is higher than ototoxicity. This may be partially due to 
the relative difficulty in assessing ototoxicity ~<hich requires the use 
of sequential audiogram and other tests that are not commonly performed 
in most clinical settings. Nephrotoxicity is usually assessed by 
monitoring various routine renal function tests such as serum creatinine 
changes. The incidence of aminoglycoside induced nephrotoxicity is 
approximately 8 to 26% of cases.3 It is generally transient and 
non-oliguric in nature and is reversible in 90% of cases after the agent 
is discontinued. Several variables have been associated vrith gentamicin 
induced nephrotoxicity. 
Host factors such as age, sex and pre-existing renal diseases have 
been studied. Kahlmeter, et al. 22 found that natients older than 60 
years had a greater mean increment of serum creatinine at the end of 
gentamicin therapy (value not shown). Hatzke, et al.23 found that in 
patients receiving gentamicin via the dosing method of ~kHenry, the mean 
age of the nephrotoxic patients ~<as significantly higher than the 
nontoxic patients (80.0 + 2.9 vs. 59.0 ~ 2.8, p<O.OS). \·,'nile in 
patients dosed according to Sawchuk and Zaske's method, the mean age was 
not significantly different between the toxic and nontoxic group. 
Taketomo, et al. 24 in a study of gentamicin nephrotoxicity also found 
that the mean age in the nephrotoxic group ,.;as significantly higher than 
the nontoxic group (65.6 ~ 14.2 vs. 59.9 ~ 16.3, p<O.OS). Other studies 
have failed to find a correlation between age and nephrotoxicity.25-31 
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Kahlmeter, et al. 22 noted the increase ir1 seru::i creatinine after 
gentamicin treatment was more pronounced in patjents with initial 
creatinine clearance less than 70 ml/min/1. 73 m2 than patients with 
greater initial creatinine clearance (mean value not shown). Matzke, 
et al.23 found that initial sert~ creatinine was significantly higher in 
the toxic patients group (mean of 1. 48 mg/ dl vs. 1. 02 mg/ dl, p<O. 01). 
Taketomo, et al. 24 and Fee, et al. 25 confirmed this finding (Taketomo, 
et al.: mean of 1.2 vs. 1.0 mg/dl, p<O.OS; Fee, et al.: mean of 1.16 
vs. 0.88 mg/dl, p<0.01). Cabrera, et al. 26 in a study of the use of 
aminoglycosides in cirrhotic patients also found that when using urinary 
beta-2 microglobulin concentration greater than 3000 mcg/L as the 
criteria for nephrotoxicity, there was a significantly higher initial 
serum creatinine (p<0.01) and a lower initial creatinine clearm;cc, 
,.., .. , 
(p<O. 001) in the nephrotoxic group. Interestingly, Hoare, et al. _')J 
found that the initial creatinine clearance was higher in the 
nephrotoxic group ( p<O. 05). The explanation \Vas that patients '.d:.:.h 
higher creatinine clearances may have a higher filtered load of 
aminot;lycosides and the proximal renal tubular cells may therefore be 
exposed to higher aminoglycoside concentrations, this then can lead to 
greater risks of nephrotoxicity. Still other studies indicate that 
there is no significant difference in the initial serum creatinine 27,28 
or creatinine clearance31,32 between toxic and nontoxic patients. 
Host univariate studies26,27 ,31 have not found any relationships 
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between sex and gentamicin nephrotoxicity However, Hoare, et al. 33 
observed in their patient population treated with gentamicin or 
tobramycin that females had a higher incidence of nephrotoxicity than 
males although this was only of borderline statistical significance 
(p=O.OS). 
Several underlying disease states have been related to the 
development of nephrotoxicity. Reymann, et al.20 in a study of patients 
receiving gentamicin or tobramycin found that volume depletion occurred 
more often in the nephrotoxic group (10 of 34) than the nonto>:ic group 
(4 of 67) (p<O.Ol). However, volume depletion occurred in five of tho 
13 patients with nephrotoxicity specifically induced by aminoglycosides 
and nine of the other 88 patients (5 of 21 patient.s 1>ith nephrotoxicity 
induced by other causes and 4 of 67 nontoxic patients), this difference 
was not statistically significant (p>O.l), thus the significance of the 
association between volume depletion and aminoglycoside induced 
nephrotO}:icity was not established. ~1oore, et al. 33 found that shock 
and liver disease occurred more often in their nephrotoxic patients (30% 
vs. 12%, p<O.OS and 30% vs. 11%, p<O.Ol, respectively). ~latzke, 
et al. 23 using pooled data from patients who received gentamicin or 
tobramycin, four,c the nephrotoxic group had a higher prevalence of 
congestive heart failure (data not shown, p<O.OS). Rush, et al. 34 
demonstrated a high prevalence of diabetes mellitus in patients with 
aminoglycoside nephrotoxicity, but there was no control group (i.e. 
patients who did not develop nephotoxicity). Moore, et al.33 did not 
10 
find a statistical association between nephrotoxicity and diabetes 
mellitus. 
!\umbers of concomitant nephrotoxic drugs was ~ound to be 
significantly greater (p<O.OS) in the nephrotoxic patients in the study 
of Taketomo, et al.24 Among these drugs, cephalosporins (especially 
cephalothin) and furosemide were two widely investigated agents in terms 
of their potential to enhance aminoglycoside nephrotoxicity and the 
results have been variable. Host studies20 • 23 • 28-30 • 33 • 35 have failed 
to demonstrate the contribution of cephalosporins to gentamicin 
nephrotoxicity. However, Plager, et al. 36 found that on post-mortem 
examinations, patients who received cephalothin and gentamicin in 
combination had more tubular hydropic degeneration or acute tubular 
necrosis than patients who received gentamicin alone (p<0.05). fong, 
et al. 30 when combining data of patients who received gentamicin or 
tobramycin, also found a significant association between concurrent 
cephalosporins and nephrotoxicity (p<O. OS), but this association was not 
significant when looking separately at patients receiving either 
aminoglycoside alone. Studies regarding the effect of concomitant 
fur osernid e have 
20,26,28,30,35,37 
also shown varying results. No st 
did not find a significant correlation 
studies 
between 
furosemide and aminogl ycoside nephrotoxicity except for one done by 
Schentag, et al. 31 They found in the nephrotoxic patients judged by 
'clinical criteria' for nephrotoxicity (i.e. rise of serum creatinine 
e;f 0. 5 mg% or more during therapy or within seven days of the last 
dose), there was a higher pre\'alence of concurrent diuretic use of which 
ll 
96% \Vas furosemide. Trollfors38 has suggested that furosemide may 
potentiate the nephrotoxicity of gentamicin by reducing glomerular 
filtration rate. 
Serum gentamicin concentrations (especially trough concentrations) 
have frequently been associated with the development of nephrotoxicity. 
Dahlgren, et al. 35 found that seven of 86 patients had a rise in serum 
creatinine during gentamicin therapy which promptly returned to normal 
upon discontinuation of treatment, and all of these seven patients had a 
trough concentration greater than 2 mcg/ml. None of the patients >.·ho 
did not have a rise in serum creatinine had a trough concentration 
greater than 2 mcg/ml, and this difference was significant (p<0.005). 
However, the time course of elevated seruin creatinine and the rise c:C 
trough concentrations was not clear in this study, at least four of the 
seven patients had their elevated trough concent!·ations measured af:e~ 
there was a significant rise (>0.5 mg%) in serum creatinine. Thereiore 
the elevated troughs could have been just a result of the already 
deteriorating renal function. Another study done by Goodman, et al.32 
reported that a trough of 4 mcg/ml or more was significantly associated 
with the development of nephrotoxicity. But the time course of rise in 
the serum creatinine and trough levels was not clear. Giamarellou, 
et al. 29 also found that trough concentrations of 2 mcg/ml or more was 
significantly associated with nephrotoxicity in gentamicin patients. 
Eight out of the ll nephrotoxic patients had trough concentrations of 2 
mcg/ml or more before the appearance of the nephrotoxicity. Taking only 
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these eight patients into consideration, there is still a significant 
association between the trough level of 2 mcg/ml or more and the 
nephrotoxicity. This association was confirmed in two other studies 
done by Hatzke, et al.23 and Cabrera, et al.26 
Smith, et a1.27 in a study of patients treated with gentamicin or 
amikacin, found that the highest trough concentration prior to the rise 
in serum creatinine in the nephrotoxic group was significantly higher 
than the highest trough concentration in the nontoxic group (p<O. 05 for 
the gentamicin group, and p<O. 01 for the ami.kacin group). Taketomo, 
et al. ,24 instead of using actual trough levels, also found that 
estimated steady-state trough concentrations based on data obtained 
during the first three days of therapy were significantly higher ir. t.iie 
nephrotoxic patients ( mean values 1.9 vs. 1.5 mcg/ml, p<O.OS). 
Schem:ag, et al. 31 and ~loore, et al., 33 found that the lr.iLial 
trough concentrations were significantly higher in the nephrotoxic group 
than the nontoxic group (mean of 1. 9 vs. 1. 3 mcg/ml, p<O. 001; mean of 
3.4 vs. 2.6 mcg/ml, p<O.OS, respectively). However, Smith, et al.27 did 
not confirm this. 
Peak gentamicin concentrations have also been investigated for 
their correlation with nephrotoxicity. Data from a study done by Smith, 
et al.27 found five of 16 patients with peak concentrations of 10 mcg/ml 
or more developed nephrotoxicity, "'bile only one of 39 patients \·:i th a 
13 
peak cone entra t ion of 1 ess than 10 P.lcg/ol developed nephrotoxicity 
(p<O.Ol). Giamarellou, et al.29 also found that more nephrotoxic 
patients (5 of 17) than nontoxic patients (2 of 50) had peak 
concentrations of 10 mcg/ml or more (p<O.OS). l·latzke, et al.23 on the 
other hand, found a higher mean peak level ( 7. 3 ± 0. 6 mcg/ml )j.n the 
nephrotoxic group than in the nontoxic group ( 5. 8 ± 0. 2 mcg/ml) ( p<(). 05). 
Hoare, et al.16 stated the initial peak concentrations were 
significantly higher (7.2 ± 0.4 mcg/ml) in the nephrotoxic patients than 
in the nontoxic patients (5.3 ± 0.1 mcg/ml)(p<O.OOl). Other 
studies20,32 have not found a relationship between high peak levels and 
nephrotoxicity. 
Other factors have f,lso been consider-ed to contribute to 
gentar.Jicin nephrotoxicity. Taketomo, et a1.24 have noted that total 
dose of gentamicin throughout the treatment period was higher in the 
nephrotoxic group (mean of 1353 mg) than the nontoxic group (mean of 
1025 mg) (p<O.OS). Fee, et al.25 similarly found that the toxic group 
had a mean total dose of 2. 67 gm while the nontoxic group hac! a rr:e:cn 
total dose of 1.64 gm and the difference was statistically 
significant (p<O. 05). Studies which did not find a significant 
association be,t\leen the total dose and nephrotoxicity have also been 
presented. 23 • 27 • 28 • 31 • 3~ • 35 • 36 Cabrera, et al. , 26 instead, found their 
nephrotoxic population had a significantly lower mean total dose (956 mg 
vs. 1582 mg, p<0.01). This was thought to be due to the dosage 
adjustment after the toxicity was identified. 
14 
Duration of therapy has also been demonstrated as a risk factor in 
gentamicin induced nephrotoxicity. 24' 27-29 Smith, et al. 27 found that 
five of eight nephrotoxic patients received more than 11 days of 
gentamicin therapy while only 14 of 89 nontoxic patients had gentamicin 
treatment of more than 11 days (p<O.Ol). Giamarellou, et al.29 found 
seven of 17 nephrotoxic patients as compared to nine of 50 nontoxic 
patients had gentamicin treatment for 10 or more days (p<O. 05). Others 
found no significant difference in the duration of gentamicin treatment 
between nephrotoxic and nontoxic patients.23,25,30-33,36 
The inconclusive results in the investigation of factors 
associated vdth clinical outcome or nephrotoxicity in gentamicin therapy 
as discussed above can at least be partially explained by the 
limitations of univariate analysis. V.1ithout controlling r.dmultaneously 
other factors, univariate analyses may fail to accurately identify and 
interpret the factors associated with outcome. Further, a ] imit ed 
number of studies have employed the multivariate analytical methods. 
Zaske, et al. 39 in the study of the treatment of burn patients 
with gentamicin used stepwise discriminant analysis to identify 
independent variables that were related to patient survival. Age, 
percent burn, individualized dosing, complication (yes/no) and 
bacteremia (yes/no) were included in the discriminant function to 
distinguish bet'''een patients survived or not throughout the pntire 
hospital course. The discriminant functions however Here not shown, and 
15 
no validation was done regarding the significance of this multi variate 
analysis. 
In a study of patients receiving gentamicin or amikacin for 
gram-negative bacteremia, Moore, et a1.16 also utilized stepwise 
discriminant analysis to examine potential multivariate association 
between the mortality and various factors including age, sex, severity 
of underlying illness, serum creatinine concentrations, diabetes, peak 
temperatures, initial leukocyte counts, microbial etiology, concurrent 
antibiotics, suspected portal of entry and initial peak concentrations. 
It was found that severity of underlying illness, initial peak 
concentrations, initial leukocyte counts, and peak temperatures were 
included in the discriminant function for patient survival. The 
discriminant equations however were neither shown, nor was there any 
validation of the discriminant functions done. 
For gentamicin nephrotoxicity, Prince, et al. 40 in the study of 
factors associated with creatinine clearance changes following 
gentamicin therapy, utilized forward stepwise multiple regression 
analysis. Using relative creatinine changes as the dependent variable, 
five independent variables were included into the regression equation, 
and the first three were clearly significant (p<O. 005 for each step), 
these are peak gentamicin level, sex (f'emale) and concomitant 
cephalothin. The authors explained the failure to detect a significant 
association between trough concentration and renal function changes by 
16 
the fact that some trough concentrations were below the sensitivity of 
the assay which may have obscured a stronger association. Also, the 
dosing regimen may have resulted in a relatively constant trough 
concentration among patients, therefore it may have failed to be 
detected in the regression analysis as a factor contributing to the 
renal function changes. 
Taketomo, et al. 24 developed two discriminant functions to 
distinguish between nephrotoxic and nontoxic groups of patients 
receiving gentamicin, these models are as follows: 
Hodel 1: 
L ~ (0.12) T dur + (0.0021) II+ (0.6J) No. of concurrent 
nephrotoxic drugs- (0.93) complicating factors (yes/no) - 0.28 
Hodel 2: 
L ~ (-0.96) complicating factors (yes/no)+ (0.56) No. of 
concurrent nephrotoxic drugs + (0.0054) D + (0.33) Cmin - 0.27 
where the numbers in parentheses represent the unstandardized co-
efficients of the independent variables, and T dur is the duration 
of therapy (day); II is the 24 hour intensity index or the product 
of intensity factor (IF) and the number of doses per day; D is the 
total dose received (mg); Cmin is the estimated minimum serum 
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concentration of gentamicin (mcg/ml); nephrotoxic drugs include 
furosemide, cephalothin, cefazolin, tetracyclines, nafcillin, 
methicillin, cimetidine, amphotericin B and polymyxin; and 
complicating factors are factors that may result in renal 
impairment (e.g. septic or traumatic shock, hepatorenal syndrome 
secondary to alcoholism, uncontrolled hypertension, metastatic 
cancer, diabetes mellitus and drug overdose). 
The probability of incorrect classification were 31. 1% and 35%, 
respectively, for Models 1 and 2. Using cross-validation, it was shown 
that there were no significant differences between the original samples 
used to develop the discriminant functions and the hold out samples used 
to validate the developed functions. 
More recently, Moore, et al.33 similarly used discrimi10ant 
analysis to develop an equation for classifying nephrotoxic and nontoxic 
patients receiving gentamicin or tobramycin. They established two 
discriminant functions, one using only those variables that can be 
obtained before treatment (Equation 1; Eq 1), the other using the 
factors known by 72 hours after treatment (Equation 2; Eq 2): 
Eq 1: 
L = (0.049) Age + (1.872) liver disease (yes =1, no =0) + (0.025) 




L = (0.333) initial 1-hour post dose level + (1.312) liver disease 
(yes = 1, no = 0) + (0.032) Age + (0.016) initial creatinine 
clearance+ (0.739) Sex (men= 0, women =1) + (0.897) Shock (yes= 
1, no = 0) - 5.357 
By using the cumulative probability curve and a nomogram that was 
developed, the probability of developing nephrotoxicity can be 
determined for new cases. There was no information given on the 
percentage of correctly identified groups, but the authors have tested 
these two models in another independent validation population and found 
the mean scores in the nephrotoxic and nontoxic groups to be 
significantly different; Eq 2 being able to discriminate better than Eq 
1. (p<0.04 for Eq 1; p<0.005 for Eq 2). 
These multivariate analyses have made it possible to 
simultaneously take into consideration different variables associated 
with patients' outcome. Nultiple regression relies on a single, 
continuous, dependent variable to define an outcome. Thus, it is 
probably not the most appropriate method to analyze a more sophisticated 
outcome such as clinical cure versus no cure or nephrotoxicity versus 
no toxicity. Since these outcomes depend on various criteria and since 
they are nominal in nature, discriminant analysis may appear to be more 
useful in identifying factors associated with these outcomes and thus 
identify patients who are at risk of nephrotoxicity or clinical failure. 
19 
This study is designed to .investigate via discriminant analysis 
the factors that are associated with the clinical outcome and 




Medical records were retrospectively reviewed for 279 patients who 
received gentamicin as treatment and were being monitored by the 
pharmacokinetic service of St. Joseph's Hospital, Stockton, California 
between June 1984 and August 1985. Among these patients, 157 were 
excluded for the following reasons: 
1. Younger than 18 years of age. 
2. Had received less than three days of gentamicin therapy. 
3. Lack of documented gram-negative infections. 
4, Had an estimated creatinine clearance of less than 
15ml/min/70kg. 
5. Had received aminoglycoside therapy less than two weeks prior 
to the gentamicin therapy. 
122 patients were included, 103 were used in the analyses for 
factors associated with clinical outcome and 120 were used for the study 
of factors associated with nephrotoxicity. 
All patients received parenteral gentamicin as treatment for their 
infections. Dosage regimens were initially individualized based on 
physician's choice of loading dose and maintenance dose; seru01 
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concentration moni taring was then implemented by the pharmacokin etic 
service of the pharmacy and was utilized as the basis of dosage 
adjustments to maintain peak serum concentrations in the range of 4 to 8 
mcg/ml and trough concentrations below 2 mcg/ml. These adjustments were 
based on the methods described by Winter.4l 
Criteria and Definitions 
Patients were classified as 'cure 1 if they remained afebrile 
(35.60 to 37 .8°C) for four consecutive days without recurrent fever or 
until they were discharged without readmission, had no leukocytosis or 
signs of infections at the portal of entry (e.g. greater than 104 
organisms/ml or greater than lO white blood cells per high power field 
in the urine, new infiltrate of chest x-ray study, positive blood 
cultures or positive wound, bile or peritoneal fluid cultures) after the 
discontinuation of gentamicin. Patients who had positive evidence of 
any of the above signs or symptoms of infections were considered 'no 
cure'. Patients who had insufficient evidence to be classified as 
'cure' or 'no cure 1 (e.g. lack of follow-up cultures in urinary tract 
infections) were excluded from the analyses for clinical outcome. 
Patients were classified as nephrotoxic if during or within five 
days after the cessation of gentamicin. therapy, they had a rise in serum 
creatinine of greater than 0.4 mg/dl when the baseline serum creatinine 
(serum creatinine within three days prior to or on the first day of 
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gentamicin therapy) was less than 3.0 mg/dl, or greater than 0.9 mg/dl 
if baseline serum creatinine was equal to or greater than 3.0 mg/dl. 
Variables tested in the analyses for clinical outcome and 
nephrotoxicity studies are listed in Table 1 and Table 2. 
Creatinine clearance was estimated by the modified method of 
Cockcroft and Gault42 based on each patient's age, sex, weight and serum 
creatinine level. This will give an estimated creatinine clearance 
corrected to 70 kg of body weight. 
Peak serum concentrations are defined as concentrations obtained 
30 minutes after the cessation of the 30-minute iilfusion. Hhile trough 
concentrations are the concentrations obtained within 30 minutes prior 
to the next dose. Initial peak and trough concentrations were taken at 
least after three or more doses of gentamicin. For the analyses of 
nephrotoAicity, total dose, duration of therapy, highest peak and trough 
concentrations were those calculated or obtained from the medical 
records until one day prior to the development of nephrotoxicity in the 
nephrotoxic patients; or those for the entire dosing period in the 
nontoxic patients. 
Other concurrent effective antibiotics are the antibiotics used 
after microorganisms being treated have been shown to be sensitive in 
the in vitro sensitivity test and include cephazolin, cefoxitin, 
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Table 1. Variables used in the analyses of clinical outcome 
Variables Definition 
* l l sex fema e=O, rna e=l 
{} 
age age in years 
LUTI" lower urinary tract infections (yes=l, no=O) 
UUTI" upper urinary tract infections (yes=l, no=O) 
. ~f pneumon1a 
bronchi tis'' 












pneumonia (yes=l, no=O) 
bronchitis (yes=l, no=O) 
septicemia (yes=l, no=O) 
wound infections (yes=l, no=O) 
abdominal infections (yes=l, no=O) 
other infections (yes=l, no=O) 
more than one infectious site (yes=l, no=O) 
pseudomonal infection (yes=l, no=O) 
more than one infectious microorganisms (yes=l, no=O) 
other concurrent effective antibiotics (yes=l, no=O) 
surgical intervention (yes=l, no=O) 
initial neutrophil count in lo3Jmm3 
peak body temperature in degree Celcius 
total dose of gentamicin in mg 
total duration of gentamicin therapy in days 
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.,, the 48-hour variables 
peak serum gentamicin concentration in mcg/ml 
trough serum gentamicin concentration in mcg/m1 
peak serum gentamicin concentration in mcg/ml 
trough serum gentamicin concentration in mcg/rnl 



















Variables used in the analyses of nephrotoxicity 
Definitions 
female~O, male~l 
age in years 
baseline serum creatinine in mg/dl 
initial estimated creatinine clearance in 
m1/min/70kg 
presence of hypotension (yes~l, no~O) 
concurrent cephalosporins (yes=l, no=O) 
concurrent furosemide (yes~l, no=O) 
number of concurrent drugs with nephrotoxic potential 
other than cephalosporins and furosemide 
total dose in mg before nephrotoxicity is observed 
duration of therapy in days before nephrotoxicity is 
observed 
initial peak serum gentamicin concentration in 
mcg/ml 
initial trough serum gentamicin concentration in 
mcg/ml 
highest peak concentration in mcg/ml before 
nephrotoxicity is observed 
highest trough concentration in mcg/ml before 
nephrotoxicity is observed 
* the 48-hour variables 
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cefamandol, cefotaxime, cefoperazone, ampicillin, carbenicillin, 
ticarcillin, piperacillin, and trimethoprim/sulfamethoxazole. 
Patients were considered hypotensive if they had a diastolic blood 
pressure of less than or equal to 40 mmHg for two consecutive days. 
Shock was defined as a systolic pressure of less than 80 mmHg with a 
urine output of less than 500 ml/24 hr or a fall in the systolic blood 
pressure of greater than 50 mmHg if the final systolic pressure was 
below 100 mmHg. 
Concomitant furosemide was only counted when furosemide was used 
before the observation of increasing serum creatinine to assure that 
furosemide is associated with the development instead of a result of 
nephrotoxicity. 
Drugs other than cephalosporins and furosemide that were 
considered to have nephrotoxic potential are amphotericin B, 
sulfonami des (including trimethop rim/ sulfametho xazol e), allop uri no 1, 
rifampin and ethambutol. 
Statistical Analyses 
Univariate analyses were conducted to compare between 'cure' and 
'no cure' groups as well as nephrotoxic and nontoxic groups. Student's 
t-test was used to compare continous variables. Chi-square test was 
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used for discrete variables with Yate' s correction if applicable. A 
p-value of 0,05 or less is considered to be statistically significant. 
Stepwise discriminant analyses were used to discriminate between 
the 'cure' versus 'no cure' group as well as the 'toxic' versus 
'nontoxic' group. A stepwise p-value of less than 0.05 was required for 
factors to enter the discriminant function. Discriminant anal.yses help 
to identify sets of variables that may be associated with nephrotoxicity 
as well as clinical failure, and they are also used in predicting future 
patients as 'cure' versus 'no cure' or 'toxic' versus 'nontoxic'. 
The Jackknife procedure was used to estimate the error rate of the 
developed discriminant functions in classifying patients' outcomes. It 
is done by omitting one patient of the population from the discriminant 
analysis, the resultant discriminant function js used to classify the 
omitted patient and the result is recorded (i.e. correct or incorrect). 
Ano<:her patient is then excluded while the first patient is put back 
into the population, and the same procedure is repeated until all 
patients have been excluded from the analysis exactly once, then the 
overall misclassification result is the unbiased estimation of the true 
error rate of the discriminant function. Classification matrices of 
each model through the Jackknife procedure were also generated for the 
convenience of interpretation. 
All statistical analyses were carried out using SPSSx (Statistical 
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Package of the Social ScienceX) program which was available through the 
Computer Center, University of the Pacific, Stockton, California. 
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RESULTS 
59 females and 63 males were entered into the retrospective study. 
The general demographic and pharmacokinetic descriptions are presented 
in Table 3 and 4. 
Evaluation of Clinical outcome 
It was possible to evaluate the clinical outcome in 103 patients 
(46 women and 57 men). Thirty-seven were classified as 'cure' while 66 
were classified as 1 no cure'. Patients were excluded when medical 
record data was insufficient to classify them as 'cure' or 'no cure'. 
The 19 patients who were excluded include 11 patients 1-i.th lower UTI, 
t1<0 with upper UTI, two with pneumoia, two with bronchitis and one with 
a wound infection. 
Comparisons between 1 cure' and 'no cure' groups for individual 
demographic and pharmacokinetic parameters are presented in Table 5 and 
6, Distribution of sites of infection was significantly different 
bet ween the 'cure' and 'no cure ' gr cups. The 'cure' group had a 
significantly higher percentage of septic patients as well as patients 
with abdominal infections (p=0.001 and p<0.01, respectively). Pneumonia 
patients had a lower cure rate than patients with other types of 
infections (p<O. 01). Lower UTI was also found to occur less often in 
the 'cure' than the 'no cure' group though this was of borde,- line 
significance (p=O.OS). 
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Table 3. Clinical descriptions of all patients--discrete variables 
Discrete Variables N 
sex (male/female) 63/59 
LUTI (yes/no) 27/95 
UUTI (yes/no) 11/111 
pneumonia (yes/no) 40/82 
bronchitis (yes/no) 9/113 
sepsis (yes/no) 24/98 
wound (yes/no) 13/109 
abdomen (yes/no) 11/111 
others (yes/no) 2/120 
multisite (yes/no) 16/106 
abx (yes/no) 63/59 
op (yes/no) 18/104 
hypotn (yes/no) 6/116 
cepha (yes/no) 46/76 
lasix (yes/no) 46/76 
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Table 4. Clinical descriptions of all patients--continuous variables 
Continous Variables 
age (year) 122 
"eight (kg) 119 
height (inch) 93 
neutrophil (103fmm3) 116 
tempmax (OC) 122 
toxins 122 
scrO (mg/dl) 122 
crcl (ml/min/70kg) 122 
td1 (mg) 122 
td2 (mg) 122 
durl (day) 122 
dur2 (day) 122 
pkO (mcg/ml) 117 
trO (mcg/ml) 118 
pkmax1 (mcg/ml) 78 
pkmax2 (mcg/ml) 73 
trmaxl (mcg/ml) 78 
trmax2 (mcg/ml) 74 
'' mean + standard deviation 
•• Mean + SD' 
65.1 + 16.6 
64.7 + 18.8 
65.8 + 5.0 
9.68 + 6.32 
38.71 + 1.00 
0.1 + 0.4 
1.14 + 0.50 
72.9 + 37.1 
1689.3 + 1134.6 
1638.0 + 1113.7 
8.1 + 4 ') 
7.8 + 4.2 
4. 75 + 2.10 
1.48 + 1.11 
6.36 + 2.08 
6.08 + 1. 75 
2.26 + 1.42 






0.4 - 42.3 
37.0- 41.3 
0 3 
0.3 - 3.8 
15 221 
380 - 7830 
160 - 7830 
3 27 
1 27 
0.8 - 16.0 
0.1 - 6.2 
3.2 - 14.4 
3.2 - 13.3 
0.5 - 7.3 
0.5 4.5 
Table 5. Univariate analysis of discrete variables of clinical outcome 
for all patients 
Variables Cure (n=37) No Cure (n=66) p 
sex(female), n(%) 15 (40.5) 31 (47.0) 0.40 * ns 
LUTI, n(%) 2 (5.4) 13 (19.7) 3.89 0.049 
UUTI, n(%) 4 (10.8) 5 (7.6) o.o4t ns 
pneumonia, n(%) 7 (18. 9) 31 (47.0) 8.01 0.005 
bronchitis, n(%) 2 (5.4) 5 (7 .6) o.oot ns 
sepsis, n(%) 15 (40.5) 8 (12 .1) 11.04 0.001 
wound, n(%) 5 (13.5) 7 (10. 6) 0.19t ns 
abdomen, n(%) 8 ( 21. 6) 3 (4.5) 
... 
7. 25' 0.007 
others, n(%) 2 (5.4) 0 (0.0) 1.35t ns 
multisi.te, n(%) 4 (10.8) 11 (16. 7) 0.65 ns 
pseudo, n(%) 13 (35.1) 33 (50.0) 2.12 ns 
multi bug, n(%) 10 ( 27. 0) 18 ( 27.3) 0.00 ns 
abx, n(%) 20 (54.1) 35 (53.0) 0.01 ns 
op, n(%) 12 (32.4) 4 (6.1) 12.57 0.0004 
* not statistically significant 
t \dth Yate 's correction 
33 
Table 6. Univariate analysis of continuous variables of clinical 












(mean ± SEH) 
63.7 + 2.9 
8.6 + 0.8 
38.6 + 0.2 
1788.8 + 220.9 
7.9 + 0.8 
4.3 + 0.3 
1.3+ 0.2 
3.5 + 0.5 
1.3+ 0.3 
,,- not statistically significant 
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No Cure (n=66) 
(mean ± SEH) 
67.9 + 1.7 
9.8 + 0.9 
38.8 + 0.1 
1724.2 + 128.9 
8. 7 + 0.5 
5.0 + 0.3 
1.6+ 0.2 






















It was found that a significantly larger number of patients 
underwent a surgical procedure for their infections in the 'cure' group 
when compared with the 'no cure' group (p<O.OOl). 
For the continuous numerical parameters, none was found to 
contribute significantly to the difference of the two groups. 
Patients who did not undergo any surgical intervention have also 
been analyzed and have been denoted as medical patients. The medical 
patients consist of 25 'cure' and 62 'no cure' patients with their data 
presented in Table 7 and 8. Septic patients continued to show a higher 
cure rate than non-septic patients (p<O.OOl). Pneumonia patients did 
not have a lower cure rate (p>O.OS). Highest peak plasma concentrations 
~<ere significantly higher in the 'no cure' group (p=O.OS). No other 
variables were found to differ significantly bet"•een the 'cure' and 'no 
cure' groups. 
!·iul ti variate stepwise discriminant analyses were further employed 
to develop models that could best describe the clinical outcome for all 
103 patients. The models generated are shown in Table 9 and 10. From 
an initial entry of all variables listed in Table 1, surgical 
intervention, sepsis, peak body temperatures, initial peak concentra~ion 
and age were sequentially included into the equation through the 
stepwise procedure. Among them, peak temperature, initial peak 
concentration and age have a negative discriminant coefficient ,,rhich 
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Table 7. Univariate analysis of discrete variables of clinical outcomes 
for medical patients 
Variables Cure (n=25) No Cure (n=62) p 
sex(female), n(%) 11 (44.0) 29 (46.8) 0.06 * ns 
LUTI, n(%) 2 (8.0) 13 ( 21 . 0) 1. zgt ns 
UUTI, n(%) 4 (16.0) 5 (8 .1) 
... 
0.51' ns 
pneumonia, n(%) 7 (28.0) 30 (48.4) 3.03 0.08 
bronchitis, n(%) 2 (8.0) 5 ( 8.1) o.oot ns 
sepsis, n(%) 12 (48.0) 7 (11.3) 14.06 0.0002 
wound, n(%) 3 (12.0) 7 (11.3) O.Olt ns 
rnultisite, n(%) 3 (12.0) 11 (17. 7) O.llt ns 
pseudo, n(%) 11 (44.0) 33 (53.2) 0.61 ns 
multi bug, n(%) 6 (24.0) 16 (25.8) 0.03 ns 
abx, n(%) 14 (56.0) 34 (54. 8) 0.01 ns 
* not statistically significant 
t with Yate's correction 
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Table 8. Univariate analysis of continous variables of clinical 












(mean ± SEM) 
65.8 + 3.4 
8.6 + 0.8 
38.7 + 0.2 
1861.8 + 300.3 
8.6 + 1.0 
4.6 + 0.3 
1.4 + 0.2 
3.3 + 0.6 
1.2+ 0.3 
~~ not statistically significant 
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No Cure (n~62) 
(mean ± SEH) 
68.0 + 1.7 
9. 7 + 1.0 
38.8 + 0.1 
1727.4 + 130.8 
8.7 + 0.5 
4.9 + 0.3 
1.6+ 0.2 
4.9 + 0.4 
1.8+ 0.2 
t p 









Table 9. Discriminant analysis of clinical outcome for all patients--
Hodel C1--all variables 
Variables Discriminant Group centroids (L)* Canonical Jackknifel't § 
Included Coefficient Cut-off point (C) Correlation Classification 
op 1.840 Lo = -0.4631 0.5298 Do Dl 
sepsis 2.015 11 0.8261 Go 52 14 66 
tempmax -0.5085 G1 14 23 ~~ ~· 
pkO -0.1020 c 0.1815 66 37 103 
age -0.01488 
constant 20.45 P( Do/Go)= 78. s;; 
P(D1/G1)=62.2% 
P(Go/Do)=67.6% 
if 0 = no cure, 1 = cure 
t prior probabilities of cure and no cure are both SO% 
§ D = group classified by discriminant function, G =actual group 
P(Do/Go) = the probability that the model can identify a patient to be 
'no cure' given that the patient is not cured 
P(D1/G1) = the probability that the model can identify a patient to be 
'cure' given that the patient is cured 
P(Go/Do) = the probability of the patient becoming not cured given that 
the model predicts so 
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Table 10. Discriminant analysis of clinical outcome for aJ.l patients--
Nadel C2--48-hour variables 
Variables Discriminant Group Centroids (L)" Canonical Jackknife"t§ 
Included Coefficient Cut-off point (C) Correlation Classification 
op 2.097 Lo -0.4200 0.4929 Do Dl 
sepsis 2.099 Ll = 0.7492 Go 52 14 66 
wound 0.8433 Go 12 25 37 
abx -0.4797 c 0. 1646 64 39 103 
constant -0.6366 
P(Do/Go)=78.8% 
P(DJ/GJ )=67 .6% 
P(Go/Do)=70.8% 
* 0 = no cure, 1 = cure 
t prior probabilities of cure and no cure are both 50% 
§ D = group classified by discriminant function, G = actual group 
P(Do/Go) = the probability that the model can identify a patient t'-' he 
'no cure' given that the patient is not cured 
?(D1/G1) ~ the probability that the model can identify a patient to be 
'cure' given that the patient is cured 
P(Go/Do) = the probability of the patient becoming not cured given that 
the model predicts so 
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means a negative association with clinical cure since the mean 
discriminant score (or group centroid) of the 'cure' group is a positive 
value of 0. 826 and the centroid of the 'no cure' group is a negative 
value of -0.463. 
Jackknife classification results showed that 52 out of 66 'no 
cure' patients and 23 out of 37 'cure' patients were correctly 
identified. By applying Bayes' rule, the probability of correctly 
predicting a patient to be not cured is 67.6% compared to the a priori 
probability of 50%. 
Similarly, another model was developed using variables available 
within 48 hours after the initiation of gentamicin therapy (the 4-3-hour 
variables in Table 1). As seen in Table 10, Model C2, surgical 
intervention and sepsis again were the first t\;o variables that entered 
the model; wound infections and other concurrent effective antibiotics 
then entered subsequently. Only 'other concurrent effective 
antibiotics' has a negative discriminant coefficient. The centroids of 
the 'cure' and the 'no cure' groups are 0.749 and -0.420, respectively. 
Jackknife classification shows that 78.8% (52/66) of 'no cure' patie>1ts 
and 67.6% (25/37) of 'cure' patients were correctly identified ai1d 
probability of the model to correctly predicting a patient to be not 
cured is 70.8% according to Bayes' rule. 
For medical patients, results of discriminant analyses are shown 
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Table 11. Discriminant analysis of clinical outcome for r.1edical patients--
~lodel C3--all variables 
Variables Discriminant Group centroids (L)* Canonical Jackknife<>t§ 
Included Coefficient Cut-off point (C) Correlation Classification 
sepsis -·2. 902 Lo 0.3546 0.4918 Do D1 
pkmax1 0.09800 L1 ~ -0.8793 Go 50 12 62 
tempmax 0.4593 G1 11 14 25 
age 0.02007 c -0.2624 61 26 87 
UUTI 1.0181 
constant -19.08 P(Do/Go)~80.6% 
P(D1/G1)~56.0% 
P(Go/Do)~64.7% 
* 0 =no cure, 1 = cure 
t prior probabilities of cure and no cure are both 50% 
§ D ~ group classj_fied by discriminant function, G ~ actual group 
P(Do/Go) ~ the probability that the model can identify a patient to be 
'no cure' given that the patient is not cured 
P(D1/G1) ~ the probability that the model can identify a patient to be 
'cure' given that the patient is cured 
P(Go/Do) ~ the probability of the patient becoming not cured given that 
the model predicts so 
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Table 12. Discriminant analysis of clinical outcome for medical patients--
Model C4--48-hour variables 
Variables Discriminant Group centroids (L)* Canonical 
Included Coefficient Cut-off point (C) Correlation Classification 
sepsis 3.143 Lo ~ -0.3033 0.4351 Do D1 
UUTI -1.151 L1 ~ 0.7521 Go 50 12 62 
abx -0.5898 G1 7 18 25 




* 0 = no cure, 1 = cure 
t prior probabilities of cure and no cure are both 50% 
§ D ~ group classified by discriminant function, G ~ actual group 
P(Do/Go) ~ the probability that the model can identify a patient to be 
'no cure' given that the patient is not cured 
PCD1/G1) ~ the probability that the model can identify a patient to be 
'cure' given that the patient is cured 
P(Go/Do) ~ the probability of the patient becoming not cured given that 
the model predicts so 
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in Table 11 and 12. From an initial entry of all variables in Table 1 
except abdominal infections, other infections and surgical intervention, 
the following variables were included in Model C3: sepsis, highest peak 
serum concentration, peak temperatures, age and upper UTI. Sepsis, 
upper UTI and other concurrent effective antibiotics were included in 
Model C4 when only the 48-hour variables were tested. From the 
discriminant coefficient of each variable and the mean discriminant 
score of each group, sepsis was again found positively correlated with 
clinical cure when other variables in the model are controlled, while 
all other factors in these models appeared to correlate with clinical 
cure negatively. Jackknife classification shows the probability of 
correctly classifying 1 no cure 1 patients is 80.6% for both models, and 
the probability of correctly predicting a new patient not to be cured is 
64,7% for Model C3 and 74.2% for Model C4, compared to the a priori 
probability of SO%. 
Evaluation of Nephrotoxicity 
One hundred and twenty patients were evaluated for nephrotixicity. 
One patient was excluded due to incomplete serum creatinine information 
while another was excluded because an episode of septic shock 
complicated the evaluation of the presence of gentamicin induced 
nephrotoxicity. 
Thirteen of the 120 patients were classified as nephrotoxic. In 
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Table 13. Univariate analysis of discrete variables for nephrotoxicity 
for all patients 
Variables Nontoxic (n=l07) Toxic (n=l3) x2 p 
sex(female), n(%) 55 (51.4) 3 (23.1) 3. 72 0.05 
hypotn, n(%) 5 (4.8) 1 ( 7. 7) o.oo" nst 
cepha, n(%) 39 ( 36.4) 6 (46.2) 0. 14" ns 
lasix, n(%) 37 ( 34.6) 8 (61.5) 2.53" ns 
lf with Yate's correction 
t not statistically significant 
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Table 14. Univariate analysis of continuous variables for 













(mean ±_ SEH) 
64.3 + 1.7 
1.1 + 0.1 
73.6 + 3.5 
0.14+ 0.04 
1672.9 + 109.8 
8.0 + 0.4 
4.3 + 0.2 
1.3+ 0.3 
3.5 + 0.3 
1.2+ 0.1 
*: not statistically significant 
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Toxic (n=13) 
(mean ±_ SEf!) 
70.2 + 2.4 
1.2+ 0.2 
72.2 + 12.3 
0.15+ 0.10 
1430.8 + 274.9 
6. 7 + 1.3 
6.9 + 1.1 
2.1 -!- 0.4 
4.0 + 1.2 
1.1 + 0.4 
t p 










the univariate analyses as shown in Tables 13 and 14, females had a 
borderline lower incidence of nephrotoxicity ( p=O. 05). Initial peak 
(p<0.001) and trough (p<0.05) concentrations are both significantly 
higher in the toxic group. No other variables tested showed significant 
differences between toxic and nontoxic patients. 
Hhen all variables listed in Table 2 were used in the stepwise 
discriminant analysis to develop a discriminant function, Hodel N1 in 
Table 15 resulted. Ten steps were performed while eight variables were 
included in the model. The eight variables entered in the model include 
initial peak concentration, sex, baseline creatinine clearance, 
concomitant furosemide, concomitant cephalosporins, age, highest trough 
concentrations and initial trough concentratioc. Duration of therapy 
was entered at step 4 but was found to be excluded again at step 10 ¥:hen 
it was detected to have failed to contribute to the discriminan;: 
function significantly. Because this equation is awkward for 
classifying patients, the Jackknife classification procedures "'ere not 
performed. 
attempted. 
Instead, a second analysis using 48-hour variables was 
As seen in Hodel N2 (Hodel 15), a much simpler model resulted. 
From the initial entry of the 48-hour variables in Table 2, initial peak 
concentration, sex, initial creatinine clearance, concomitant 
cephalosporins and age sequentially entered the model and all are with a 
positive correlation with nephrotoxicity. Jackknife procedure shows 
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Table 15. Discriminant analysis of nephrotoxicity--
Model N1--all variables 
Variables Discriminant Group centroids (L)* Canonical Jackknife 
Included Coefficient Cut-off point (C) Correlation Classification 
pkO 0. 3569 Lo = -0.2002 0.5012 








* 0 = nontoxic, 1 = toxic 
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Table 16. Discriminant analysis of nephrotoxicity--
Hodel N2--48-hour variables 
Variables Discriminant Group centroids (L)* Canonical Jackknife~- t§ 
Included Coefficient Cut-off point (C)t Correlation Classification 
a.t 
pkO 0.4488 Lo -0.1752 0.4520 Do Dl 
sex 1.140 L1 1.442 Go 105 2 107 
crcl 0.01562 G1 10 3 13 
cepha 0.5940 Ca ~ 1.937 115 5 120 
age 0. 01883 cb ~ 0.6334 
constant -5. 246 P(Do/Go)~98.1% 




Go 86 21 107 
Gl 6 7 13 
92 28 120 
* 0 ~ nontoxic, l ~ toxic 




§ D ~ group classified by discriminant function; G ~ actual group 
P(Do/Go) ~ the probability that the model can identify a patient being 
nontoxic given that the patient is nontoxic 
P(D1/G1) ~ the probability that the model can identify a patient being 
toxic given that the patient is toxic 
P(G1/D1) ~ the probability of a patient becoming toxic given that the 
model predicts so 
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that when the prior probability is chosen to be 10.8% based on the 
actual size of toxic patients in the patient population, there is a 
23.1% probability of correctly identifying a nephrotoxic patient. In 
the meantime, there is a 60.6% probability of correctly predicting a 
patient to be nephrotoxic, 
Due to the fact that 76.9% of the nephrotoxic patients were 
actually misclassified (P(D1/G1)~23 .1% ), the prior probability of 
nephrotoxicity was raised to SO%. This resulted in an increased 
sensitivity of the model to detect nephrotoxic patients (53.8%) although 
it also sacrificed the accuracy in classifying nontoxic patients from 
98.1% to 80.4%. The probability of correct prediction of a new patient 
to be nephrotoxic became 73.3% based on Bayes' rule as opposed to the 
50% prior probability. 
A third model, Model N3 (Table 17), was developed when sex was 
excluded from the 48-hour variables. This model included the variables 
of initial peak concentration, initial creatinine clearance, concurrent 
furosemide and age. The probability of correctly classifying a 
nephrotoxic patient is 15.4% when the prior probability of 
nephrotoxicity is chosen to be 10.8%. This improved and became 46. 2% 
when SO% is used as the prior probability of toxicity. l<'hen the 
canonical correlation coefficients which measure the correlation between 
the discriminant function and the differences between the two groups 
were compared, Model N3 had a weaker discriminant power than Model N2. 
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Table 17. Discriminant analysis of nephrotoxicity--
Hodel N3--48-hour variables excluding sex 
Variables Discriminant Group centroids (L)* Canonical 
Included Coefficient Cut-off point (C)t Correlation Classification 
pkO 0.4381 Lo = 
crcl 0.01532 L1 = 
lasix 0.6033 
age 0.02002 Ca = 
constant -4.666 Cb = 






























t a prior probability of nephrotoxicity = 10.8%, b = 50.0% 
§ D = group classified by discriminant function; G = actual group 
P(Do/Go) = the probability that the model can identify a patient being 
nontoxic given that the patient is nontoxic 
P(D1/G1) = the probability that the model can identify a patient being 
toxic given that the patient is toxic 
P(G1/D1) = the probability of a patient becoming toxic given that the 
model predicts so 
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For the convenience of future classification, a cumulative 
probability curve for Model N2 with 50% prior nephrotoxicity probability 
was developed (Figure 1). By calculating a new patient's discriminant 
score and plotting it on the abscissa then projecting it onto the curve, 
the probability of the patient developing nephrotoxicity can be 
estimated from the ordinate. This curve provides an alternative patient 
classification method, instead of using a fixed cut-off point and 
rigidly assigning patients dichotomously into the nephrotoxic or 
nontoxic group, the likelihood of a patient developing nephrotoxicity 
can now be found. 
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-4.0 -3.0 -2.0 -1.0 0.0 1.0 2.0 3.0 4.0 
Discriminant Score 
Fig. 1. Expected probabilty of nephrotoxicity 
development given the discriminant scores 
based on Model N2 and an a priori probability 
of nephrotoxicity of 50%. 
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DISCUSSION 
Factors associated with clinical outcome and nephrotoxicity in 
patients receiving aminoglycoside antibiotics continue to be 
controversial. Although many researchers have tried to define the 
relationship of various demographic and pharmacokinetic variables to 
clinical outcome or nephrotoxicity, the results have been inconsistent. 
The inconsistency of the previous studies may be explained by the 
utilization of univariate statistical analyses. This study thus 
utilized both univariate and multi variate techniques in an attempt to 
better define the factors associated with the clinical outcome 6nd 
nephrotoxicity in patients receiving gentamicin. 
The discrepancies between the univariate and multi variate ar;2.lyses 
are apparent in the analyses for clinical outcome. Nore pneumonia 
patients had clinical failure in the univariate analysis for all 
patients, this is consistent with some earlier reports.S This site 0f 
infection ceased to contribute to the difference of clinical outcome 
\-<then stepv.•ise discriminant analysis was done. The reason for this 
discrepancy is not clear since pneumonia was not found to correlate with 
any other tested variables significantly. One possible explanation is 
that other underlying factors which were not tested in this study may in 
fact correlate with pneumonia and contribute significantly to the 
difference between the 'cure' and 'no cure' groups; while in the 
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discriminant model developed, pneumonia per se could not contribute 
significantly to this difference thus was left out of the model. 
The prevalence of abdominal infections also appears to be 
significantly greater in the 'cure' than 'no cure' groups. l1'hcn the 
correlation matrix of all variables tested were examined, a high 
correlation between abdominal infections and surgical intervention ;:as 
found (r=0.79). Therefore, when surgical intervention was in the model, 
1 abdominal infections' was not able to provide additional significant 
information to the discriminant model. 
Factors tested and found not to differ significantly bet,,·een 
'cure' and 'no cure' groups in the univariate analyses and ::-{et v:ere 
included in Model Cl are peak temperature, Gge and initial peak 
concentration. Since the mean discriminant score or centroid of the 
'cure' group is a positive value, the negative discriminant coefficients 
of peak temperature and age suggest a negative correlation with clinical. 
cure. That is, the older the patient or the higher the body 
temperature, the less likely that the patient was cured. It is, 
however, hard to explain the negative correlation between initial peak 
concentration and clinical cure except that this may have reflected the 
more aggressive treatment initially in patients who had more critical 
clinical status. 
Two factors have consistently appeared in both the univariate and 
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discriminant analyses for Models Cl and C2, one being surgical 
intervention, the other, sepsis. Both of these variables were found to 
correlate positively with clinical cure. Surgical intervention is a 
routine treatment in disease states such as appendicitis, cholecystitis 
and abscesses. Antibiotics in these cases often only play an auxiliary 
role. Therefore, in the absence of post-operative complications, 
surgical intervention can be expected to correlate positively with 
clinical cure. 
The reason for a positive correlation between sepsis and clinical 
cure is not readily apparent. It was suspected that septic patients may 
have received more aggressive treatment in terms of their duration of 
therapy, total dose or serum concentrations. However, a univariate 
comparison and the multivariate correlation matrix have both failed to 
find any evidence indicating that this was the case. 
possible that in some of the septic patients (10/ 23), no focus of 
infection was identified, therefore based on the criteria of clinical 
cure, only the systemic signs and symptoms of sepsis and blood cultures 
can be evaluated. The possible presence of occult infections at the 
focus may have been overlooked and some of these patients may have been 
falsely classified as 'cure'. 
Hhen the 48-hour variables were analyzed in Model C2, surgical 
intervention, sepsis, wound infections and other concurrent effective 
antibiotics were included besides the aforementioned surgical 
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intervention and sepsis. '\11ound infecti:ms' is positively correlated 
while other 'concurrent effective antibiotics' is negatively correlated 
with clinical cure. It was found that in the univariate analysis, the 
'cure' group has slightly higher rather than lower percentage of 
patients treated with concurrent effective antibiotics although this was 
not statistically significant. The negative discriminant coefficient 
thus can only be explained by some unknown correlation of the concurrent 
antibiotics with the other variables already in the models. The 
clinical si.gnificance of this observation is of questionable value. 
Since surgical intervention was consistently the first variable to 
enter the discriminant function during the stepwise procedure whi:.e 
surgery itself may be a decisive factor for clinical outcome, ;1e decided 
to evaluate patients who did not undergo any surgery. 
The variables included in Models C3 and C4 overlapped wtth r1odels 
Cl and C2 with only 2 exceptions. The variables that overlapped between 
C3 and Cl include sepsis, peak temperature and age while the highest 
peak concentration instead of initial peak concentration was included in 
Model C3. Upper UTI is another new variable appeared in Model C3. 
Variables overlapped between Models C4 and C2 include sepsis and other 
effective antibiotics. But upper UTI rather than wound infections was 
enterd into Model C4 as compared to Hodel C2. This indicates that 
although surgical intervention played an important role in contribuing 
to patients' cure, the other factors that influenced the results of 
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gentamicin treatment are essentially the same for all patients, Both 
the highest peak concentration in Hodel C3 and the initial peak 
concentrations in Hodel Cl are negatively correlated with clinical cure 
and this probably is a result rather than a cause of clinical failure. 
Upper UTI was included in both Hodels C3 and C4 and it has an 
apparently negative association with clinical cure. Interestingly, in 
the univariate comparison of the 'cure' and 'no cure' groups, the 'cure' 
group actually had a higher percentage of patients with upper UTI. By 
further investigation of the correlation between each pair of variables 
in the analysis, it was found that upper UTI has a relatively high 
positive correlation with sepsis (r=0.55). Thus, when sepsis was 
previously in the model, upper UTI ceased to contribute positi·:ely to n 
significant extent to clinical cure, that is, when sepsis and other 
variables already in the model are controlled for, upper UTI contributes 
negatively to clinical outcome which was masked in the univariate 
analysis. Although this can technically explain the apparent 
differences between the univariate and multivariate models, the true 
relationship of upper UTI and clinical outcome in the population is not 
clear. 
It was hoped that through these analyses, factors that can be 
easily monitored and controlled through the treatment period could be 
identified to increase the probability of clinical cure. From the 
results, surgical intervention played an important role in determining 
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clinical outcome. Older patients and those with higher temperatures 
were at higher risks of treatment failure. However, parameters that 
were used to attempt to reflect the aggressiveness of the treatment, 
such as serum gentamicin concentrations, duration of therapy, total dose 
and other concurrent effective antibiotics, were not demonstrated to 
increase the probability of clinical cure. In this study, none of the 
serum concentration measurements have been positively associated with 
cure. This may have been due to the fact that for most patients, the 
peak serum concentrations were in the 4 to 8 mcg/ml range via the 
pharmacokinetic service. Noone, et al. 15 had suggested that cure rate 
would be higher if peak concentration is above 5 mcg/ml for most 
infections. Since the patients had serum concentrations maintained 
within this therapeutic peak range, the small differences in the peak 
concentrations probably would not discriminate between clinical 
outcomes. 
There are other variables which were reported to contribute to 
clinical outcome in patients treated with aminoglycosides and yet not 
included in this study. Severity of underlying diseases have been shown 
to influence clinical outcome in some studies.l2,13 The failure to 
include this variable in the study may have diminished the ability to 
dicriminate between the 'cure' and 'no cure' groups. \villiams, et al.l9 
in a recent study of patients treated with amikacin have reported that 
HIC, intensity factors which also requires the knowledge of MIC, and the 
ratio of mean peak concentration and MIC all correlate significantly 
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with patients 1 clinical outcome in the discriminant analysis. In a 
retrospective study done by Deziel-Evans, et al. ,43 several 
pharmacokinetic indices which constituted certain measurement of serum 
concentration relatively to MIC were all found to correlate positively 
with clinical outcome. Due to the lack of routine measurement of MIC in 
this hospital setting where the data was obtained, it was not possible 
to include any variable relating to MIC in the analyses. 
study included the most commonly obtainable variables in a community 
hospital setting and while the discriminant functions developed did 
disclose some correlation between these variables and clinical outcome, 
the inclusion of MIC related variables and underlying diseases may have 
changed the results. 
Besides the identification of potential discrj~minators of two 
distinct groups, discriminant functions can also be used to classify nmv 
patients. With all the aformentioned models in the study, an unbiased 
statistical method, namely, the Jackknife procedure was utilized 
validate the models. This procedure is used to estimate the accuraci of 
these models to classify the original patients as well as to predict new 
patients 1 outcomes. The latter is estimated based on the application 
of Bayes 1 rule. 
For models of clinical outcome, since the prior probability of 
clinical outcome is both 50%, the classification cut-off point is the 
point half-way between the mean discriminant score (group centroid) of 
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each group . By calculating each patient's discriminant score , it can 
then be compared with th e cut- off point and the patient can be 
classified or predicted t o be cured or not cured . Let Do represent that 
the patient is c l assified to be 'no cure ' based on the discriminant 
score and Go r e present that the patien t is t ruly a ' no cure ' patient, 
th en P(Do/Go) s hows the se nsitivity of the discriminant model to 
identify a patient who i s known to be 'no cure '. Similarly, P(D1/G1) 
shows the sensitivity of the model to identify a known cured patient 
where D1 r epresents tha t the patient is classified as ' cure ' based on 
the discriminant score and G1 r eprese nts that a patient i s known to be 
cured . P(Go/Do) , on the other hand , shows the probabili ty of the model 
to correctly predict a new patient to have a clinical failure. All four 
model s (Cl to C4) were able to identify 'no cure ' patients more r eadily 
than the ' cure ' patients (i.e . P(Do/Go) > PCD1/G1)) . All models ::an 
improve the accuracy of predicting a new patient to be 'no cure ' (i . e . 
P(Go/Do)) by 15 to 25% compared to the a priori probability of 50% . 
By examining the canonical corre l a tion coefficients \"hich 
represent the correlation of each model with the differ e nces of t he two 
groups , it was found that none of the models explained mor e than 30% of 
the differences of the two groups (squared value of the canonical 
correlation) . Therefore a l though the models developed do serve as tools 
to identify some factor s that are associated with clinical outcome in 
patients treated with gentamicin , and can improve the prediction of the 
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patients' clinical outcomes, they can ortly explain partially the 
differences between patients that have clinical cure and failure. As 
suggested by other studies, some more sophisticated pharmacokinetic 
variables such as intensity index, ratio of peak serum concentration to 
~1IC as well as the consideration of severity of underlying disease 
states need to be considered to improve further the discrimination. 
In the analyses for risk factors of gentamicin nephrotoxicity, 
10.8% of our patients were defined as having developed nephrotoxicity 
which is consistent with the approximate population incidence of 8 to 
26%.3 
Besides the univariate analyses, three discriminant models were 
developed. Model Nl was developed based on the entry of all variables 
in Table 2. Of the three concentration measurements in the model, there 
is a relatively high correlation between highest trough concentration 
with both the initial peak (r=0.364) and initial trough (r=0.531), it is 
therefore hard to interpret the signs of these coefficient terms. 
Models N2 and N3 were then developed based on fewer variables that were 
obtained within the first 48 hours of gentamicin therapy. 
From both the univariate and the multivariate analysis, the 
initial peak serum concentration of gentamicin shows a strong 
correlation with the development of nephrotoxicity. This finding is 
consistent with several previous stud ies.33,40 The initial trough 
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concentration, although found to differ significantly (p=0.026) in the 
univariate comparison between toxic and nontoxic groups, was included in 
only the discriminant function Model Nl. In Model Nl where all possible 
variables were tested, eight variables entered the model with the 
initial peak concentration as the first variable entered, while initial 
trough concentration entered at the 9th step. This indicates that the 
initial peak has a much stronger correlation with nephrotoxicity than 
initial trough concentration. In other models when 48-hour variables 
were tested, initial peak concentration continued to be the first 
variable to enter each model while initial trough was excluded. Hhen 
trough concentrations are maintained in the previously defined 'nontoxic 
range' (i.e. less than 2 mcg/ml), there is little concentration 
variability and it cannot be used to discriminate between nephrotoxic 
and nontoxic patient groups. The fact that initial peak and trough 
concentrations are significantly correlated (r=O. 528) may also prevent 
the initial trough concentrations to enter the model. 
Duration of therapy has also been reported to correlate 
significantly with aminoglycoside nephrotoxicity in both univariate and 
multi variate studies .19 • 24 • 27-29 Williams, et al. 19 in the stepwise 
discriminant analyses of factors associated with nephrotoxicity in 
patients receiving amikacin noted that days of therapy was the sole 
factor included in the stepwise discriminant function which was 
positively correlated with the development of toxicity. However, it is 
found in this study that duration of therapy although included in Model 
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N1 at step 4 was again excluded at step 10 due to loss of significant 
association with the outcome after all other variables entered the 
model. Examining the results from univariate analysis, duration of 
therapy was not significantly different between toxic and nontoxic 
groups with the mean value slightly higher in the nontoxic group. Since 
this variable reflects the duration of therapy before nephrotoxicity is 
observed, the relatively short duration of therapy in the toxic group 
(mean of 6. 7 days) suggests that at least some patients developed 
apparent nephrotoxicity early in the therapy. Indeed, four out of 13 
nephrotoxic patients developed nephrotoxicity within the first three 
days of therapy. Although this is relatively unusual for classical 
aminoglycosides induced nephrotoxicity, no other identifiable causes 
could be found to explain the rise of serum creatinine except for one 
who had preexisting lupus nephritis. True contribution cf d•1ration of 
therapy to the development of aminoglycoside induced nephrotoxicity 
therefore requires further study with possibly larger sample of 
nephrotoxic patients. 
With regard to the development of nephrotoxicity, sex has been a 
controversial factor. In studies done previously, most univariate 
studies have not found a correlation between sex and gentamicin 
nephrotoxicity. Two multivariate analyses, 33,40 however, have 
independently found that sex was included in their multi variate models 
in which females seem to be more prone to the development of 
nephrotoxicity. This study, indicates that males are more likely to 
develop nephrotoxicity in the univariate as well as the multivariate 
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analyses. This opposite finding further complicates the picture of the 
relationship between sex and nephrotoxicity for which a postulated 
explanation has never been given. 1\Thether the result is an artifact is 
not certain since the number of nephrotoxic patients in this study as 
well as the two previous studies are relatively small. Further 
investigations will be needed to clarify the possible correlation of sex 
and aminoglycoside induced nephrotoxicity. Because the results of this 
study opposed those of previous investigations, sex was excluded from 
the analysis and Model N3 was developed. 
Some studies22-24 have confirmed that age is a risk factor for the 
development of nephrotoxicity in patients receiving ami nogly co sides 
though others have not. 25-31 In this patient population, the mean age 
is 65 years. The results from discriminant analyses (Models N2 and N3) 
suggest that with all other factors remaining constant, the older the 
patient, the higher the risk of nephrotoxicity. 
Models t\2 and t\3 also indicate that the higher a patient's initial 
creatinine clearance, the more likely the patient will develop 
nephrotoxicity. This is contrary to many previous studies which showed 
that nephrotoxic patients had higher mean initial serum creatinine along 
with lower mean initial creatinine clearance and implied that patients 
with preexisting compromised renal function may be more prone to 
toxicity. However, this result is consistent with another multivariate 
study done by Hoore, et al.33 They pointed out that in the previous 
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studies, doses were not adjusted according to plasma levels and the 
presence of high serum concentrations in patients with compromised renal 
function may be the real cause of the toxicity. In patients whose serum 
aminoglycoside concentrations are in the therapeutic range, those 
patients 1dth better renal functions may in fact have a higher filtered 
load of aminoglycoside and their renal tubules are exposed to higher 
concentrations of aminoglycosides thus leading to a greater risk of 
nephrotoxicity. Patients whose estimated creatinine clearances are 
below 15 ml/min/70kg have been excluded in this study and serum 
gentamicin concentrations were routinely monitored for all patients and 
maintained in the therapeutic range. As a result, this study supports 
the idea that when all other factors are controlled, higher creatinine 
clearance actually predispose patients to greater risk of aminoglycoside 
induced nephrotoxicity. 
Concomitant cephalosporins was another variable included in Model 
N2. Cephalosporins in combination with aminoglycoside treatment has long 
been suspected to enhance aminoglycoside induced nephrotoxicity. 36 • 40 
Cephaloridine and cephalothin are the cephalosporins that have been 
commonly incriminated as enhancing aminoglycoside nephrotoxicity. Due 
to the lack of definite information on other cephalosporins, all 
cepha lospor ins used in 
study. Interestingly, 
the patient population were included in the 
when the 48-hour variables were used, the 
variable 'concomitant cephalosporins' was included in the discriminant 
function with a positive association with toxicity. But when sex was 
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excluded from the 48-hour variables (Hodel N3), 'concomitant furosemide' 
instead of cephalosporins entered the model. Furosemide has also been 
incriminated as a risk factor for the development of aminoglyco side 
nephrotoxicity. 31 • 38 There is no readily available explanation for the 
discrepancy of ~lodel N2 and N3, and since both of these agents were 
included in No del N1 as well, it is suggested that both concomitant 
cephalosporins and furosemide may really play a role in enhancing 
gentamicin nephrotoxicity. Caution therefore should be taken when these 
agents are used in combination with aminoglycosides. 
Nodels developed for nephrotoxicity analyses were also tested by 
Jackknife procedure except for Model N1 since this model encompasses 
relatively large numbers of variables which is difficult to interpret 
and impractical to use. Jackknife procedures were applied to the simple 
models (Models N2 and N3). Hhen 10.8% was used as the a priori 
probability of nephrotoxicity occurring, the cut-off points (l. 937 for 
Model N2 and 2.069 for Model t\3) are chosen based on a linear 
combination of the midpoint of the two centroids and the natural 
logarithm of the ratio of the prior probabilities of the two groups. As 
seen in the classification matrices, although both models raised the 
probability of correctly predicting a new patient to be toxic (P(G1/D1ll 
from 10.8% to 60.0% (Model N2) and 50.0% (Model N3), these models can 
only correctly identify approximately 20% of the known toxic patients 
(P(D1/G1) = 23.1% for Model N2, 15.4% for Model N3), that is to say that 
these models can overlook a significant number of toxic patients. It 
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is important to be able to identify nephrotoxic patients, yet the models 
derived in the manner noted above did not perform as well as had been 
expected. The a priori probability of toxicity was therefore raised to 
increase the cost of misclassifying a nephrotoxic patient as a nontoxic 
patient. By shifting the cut-off point more toward the nontoxic 
centroid, the probability of misclassifying a toxic patient to be 
nontoxic can be lowered as depicted in Figure 2. It can also be seen 
from Figure 2 that by choosing the cut-off point at the midpoint of the 
two centroids, the total misclassification probabilities can be 
minimized. As the prior probability of toxicity was raised to 50%, the 
cut-off point is 0.6332 for Model N2 and 0.5401 for Model N3. Hhile 
Model N3 was done excluding sex from the analysis, it cannot 
discriminate toxic from nontoxic patients as well as ~lodel N2 as judged 
by the canonical correlation. It is therefore thought that Hodel N2 
with 50% prior probability of toxicity is the best model developed in 
terms of the ability to classify and to predict a nephrotoxic patient as 
well as the convenience in application. 
Besides using a cut-off point to classify or predict a patient's 
outcome, a cumulative probability curve was also developed for Model N2 
with a 50% prior probability of toxicity (Figure 1). This curve allows 
one to estimate the probability of a new patient developing 
nephrotoxicity. To illustrate the use of the probability curve and 
Model N2, the following example is used. A 66 year-old male with 
initial estimated creatinine of 70ml/min/70kg received gentamicin 
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Fig. 2. Theoretical distributions of nontoxic (G0 ) and toxic ( G 1) 
groups with L0 and L1 being the centroid or each group. 
Cut-off points Ca = 1 . 9 3 7 is based on prior probab i I ity of 
1 0.8% and cb = 0.6334 is based on prior probability of 
SO%. Shaded areas represent the probability of 
misclassifying nephrotoxic patients as nontoxic patients. 
( DID: when Ce. is used as the cut-off point and 
E3: when cb is used as the cut-off point) 
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without other concomitant antibiotics. The initial serum peak 
gentamicin concentration is 8.5 mcg/ml, the discriminant score = 0.4488 
X (8,5) + 1.140 X (l) + 0.01562 X (70) + 0,5940 X (0) + 0.01883 X (66) -
5.246 = 2.045, by plotting this onto the abscissa in Figure 1, the 
corresponding probability can be found to be about 91% on the ordinate 
which indicates a high risk of nephrotoxicity development. 
Initial peak concentration was included in Models C1, N1, N2 and 
N3. Based on the findings that initial peak gentamicin concentration 
does not contribute to the clinical cure positively (Model C1) and yet 
is positively associated with the nephrotoxicity (Models N1 to N3), one 
should calculate the initial dose to avoid high initial peak 
concentrations. It should also be kept in mind that mean peak 
concentration should be maintained high enough above MIC since this has 
been found to correlate positively "ith clinical cure. 19 • 43 One other 
finding is that the concomitant use of cephalosporins is positively 
correlated \dth nephrotoxicity, ,;hile the use of concurrent effective 
antibiotics which include largely cephalosporins was not found to 
significantly benefit the clinical outcome of patients (Models C2 and 
C4), choice of concomitant antibiotics should therefore be made ,;i th 
discretion. In the presence of other risk factors of nephrotoxicity 
such as high initial peak gentamicin concentration, concomitant use of 
furosemide and old age, unless synergistic use of cephalosporins and 
gentamicin is indicated, cephalosporins should be avoided if possible. 
Sex, age, site of infections, and creatinine clearance are variables 
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that cannot be therapeutically manipulated, but they may be useful as 
predictors of patients' clinical outcome or the likelihood of developing 
nephrotoxicity. 
This study is not without limitations. Due to the retrospective 
nature of the study, various data that may be associated with clinical 
outcome and nephrotoxicity were not collected. The lack of availability 
of these other variables may have inhibited the development of more 
sensitive and specific models. Lack of follow-up data after the 
patients are discharged from the hospital may also have limited our 
evaluation of the paitents' clinical outcomes and possible delayed 
nephrotoxicity. Therefore, if these conditions are altered, the results 
presented above may not apply. 
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CONCLUSIONS 
Discriminant analysis used as a tool in statistical analyses can 
reveal the multivariate differences between two or more groups and can 
further be used for classification purposes as demonstrated above. 
Higher body temperature and older age are found to be negatively 
associated with clinical cure in patients treated with gentamicin in the 
multivariate ana lysis. Surgical intervention, on the other hand, 
appeared to be beneficial to patients' clinical outcomes in patients who 
need it. Other variables not tested such as MIC, intensity factors, 
severity of underlying diseases may further aid in the interpretation of 
the differences in patients' clinical outcomes as well as i_n the 
predktion of membership of individual cases. 
~1ale sex, older age, higher creatinine clearance, concomitant 
cephalosporins and furosemide and most importantly, the high initial 
peak serum concentration of gentamicin, are found to be able to 
predispose a patient to nephrotoxicity. Model N2 is especially useful 
for the purpose of early detection of renal function decline. 
Based on these findings, efforts should be made toward balancing 
clinical cure and nephrotoxicity especially in the elderly when 
gentamicin is used. At the same time, more multivariate studies should 
be conducted to disclose the risk factors of clinical failure and 
71 
nephrotoxicity in patients treated with gentamicin as well as the 
pathophysiology of aminoglycoside induced nephrotoxicity. 
72 
BIBLIOGRAPHY 
1. l<einste in MJ, Luedemann GM, Oden EM, et al. Gentamicin, a new 
antibiotic complex from Micromonospora. J Med Chern. 1963;6:463-64. 
2. Rosselot JP, Marquez J, Meseck E, et al. Isolation, purification, 
and characterization of gentamicin. In: Sylvester JC, eds, 
Antimicrobial agents and chemotherapy-1963. Ann Arbor: American 
Society for Microbiology, 1964:14-16, 
3. Sande MA, Mandell GL. Antimicrobial agents--the aminoglycosides. 
4. 
In: Gilman AG, Goodman LS, Rall TH, Murad F. The pharmacological 
basis of therapeutics. 7th ed. New York: MacMillan, 1985: 1150-69. 
Cox CE. Gentamicin, a new aminoglycoside antibiotic clinical and 
laboratory studies in urinary tract infection. J Inf Dis. 
1969;119:481-91. 
5. Shimizu K. Clinical experience with gentamicin in Japan. J l:lf Dis. 
1969;119:448-52. 
6, Bodey GP, Middleman E, Umsawasdi T, Rodriguez V. Intravenous 
gentamicin therapy for infections in patients with cancer. J Inf 
Dis. 1971;124 (suppl.):174-79. 
7. Bodey GP, Middleman E, Umsawasdi T, Rodriguez V. Infections in 
cancer patients-results with gentamicin sulfate therapy. Cancer. 
1972;29:1697-701. 
8. Klastersky J, Daneau D, Swings G, lveerts D. Antibacterial activity 
in serum and urine as a therapeutic guide in bacterial infections. 
J Inf Dis. 1974;129:187-93. 
73 
9. Klastersky J, Hensgens C, Henrl A, Daneau D. Comparative clinical 
study of tobramycin and gentamicin. Antimicrob Agents Chemother. 
1974;5:133-38, 
10. Athlin L, Dome1lof L, Holm S. Gentamicin treatment in severe 
surgical infections- serum levels, interations, toxicity and 
efficacy. Acta Chir Scand. 1981;147:225-30. 
11. Del Rosal,PL. A comparative study of the efficacy and safety of 
azlocillin and gentamicin in the treatment of serious infections. J 
Antimicrob Chemother. 1983;11(suppl.B):159-67. 
12. Jackson GG, Riff LJ. Pseudomonas bacteremia: pharmacologic and 
other bases for failure of treatment with gentamicin. J Inf Dis. 
1971;124(suppl.):S185-91. 
13. Parry MF, Neu HC. A comparative study of ticarcilin plus tobramycin 
versus carbenicillin plus gentamicin for the treatment of serious 
infections due to gram-negative bacilli. Am J Med, 1978;64:961-66. 
14. Gonzalez MA. A comparison of azlocillin and gentamicin in the 
treatment of serious infections caused by pseudomonas aerugenosa. J 
Antimicrob Chemother. 1983;11(suppl.B):169-74. 
15. Noone P, Parsons THC, Pattison JR, Slack RCB, Garfield-Davis D, 
Hughes K. Experience in monitoring gentamicin therapy during 
treatment of serious gram-negative sepsis. Br Med J. 1974;1:477-81. 
16. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside 
plasma levels with mortality in patients with gram-negative 
bacteremia. J Inf Dis. 1984;149:443-48. 
74 
17. Lindahl F, Bagerskov A. A survey of 99 srugical patients treated 
with gentamicin. Acta Chir Scand. 1973;139:368-71. 
18. Gilbert DN, Eubanks N, Jackson J. Comparison of amikacin and 
gentamicin in the treatment of urinary tract infections. Am J Med. 
1977; 62:924-29. 
19. Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin HA. Factors 
associated with nephrotoxicity and clinical outcome in patients 
receiving amikacin. J Clin Pharmacol. 1986;26:79-86. 
20. Reymann MT, Bradac JA, Cobbs CG, Dismukes WE. Correlation of amino-
glycoside dosages with serum concentrations during therapy of 
serious gram-negative bacillary disease. Antimicrob Agents 
Chemother. 1979;16:353-61. 
21. McCabe WR, Jackson GG. Gram-negative bacteremia. I. ·etiology and 
ecology. Arch Intern Med. 1962;110:847-64. 
22. Kahlmeter G, Hallberg T, Kamme C. Gentamicin and tohramycin in 
patients with various infections-nephrotoxicity. J Antimicrob 
Chemo. 1978;4 (suppl.A):47-52. 
23. Matzke GR, Lucarotti RL, Shapiro HS. Controlled comparison of 
gentamicin and tobramycin nephrotoxicity. Am J Nephrol. 
1983;3:11-17. 
24. Taketomo RT, McGhan WF, Fushiki MR, Shimada A, Gumbert NF. 
Gentamicin nephrotoxicity: application of multi variate analysis. 
Clin Pharm. 1982;1:544-48. 
25. Fee WE, Vierra V, Lathrop GR. Clinical evaluation of aminoglycoside 
toxicity: tobramycin versus gentamicin, a preliminary report. J 
75 
Antimicrob Chemother. 1978;4(suppl.A):31-36. 
26. Cabrera J, Arroyo V, Ballesta AM, Rimola A, Gual J, Elena N, Rodes 
J. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary 
beta-2 microglobulin to discriminate functional renal failure from 
acute tubular damage. Gastroenterology. 1982;82:97-105. 
27. Smith CR, Maxwell RR, Edwards CQ, Rogers JF, Lietman PS. 
Nephrotoxicity induced by gentamicin and amikacin. Johns Hopkins 
~led J. 1978; 142:85-90. 
28. Smith CR, Lipsky JJ, Lietman PS. Relationship between amino-
glycoside-induced nephrotoxicity and auditory toxicity. Antimicrob 
Agents Chemother. 1979;15:780-82. 
29. Giamarellou H, Metzikoff C, Papa Christophorou S, Dontas AS, Daikos 
GK. Prospective comparative evaluation of ger.tamicin or gentamicin 
plus cephalothin in the production of nephrotoxicity in roan. J 
Antimicrob Chemother. 1979;5:581-90. 
30. Fong HI, Fenton RS, Bird R. Comparative toxicity of gentamicin 
versus tobramycin: a randomized prospective study. J Antimi crob 
Chemother. 1981;7:81-88. 
31. Schentag JJ, Cerra FB, Plaut ME. Clinical and pharmacokinetic 
characteristics of aminoglycoside nephrotoxicity in 201 critically 
ill patients. Antimicrob Agents Chemother. 1982;21:721-26. 
32. Goodman EL, Van Gelder J, Holmes R, Hull AR, Sanford JP. 
Prospective comparative study of variable dosage and variable 
frequency regimens for administration of gentamicin. Antimicrob 
Agents Chemother. 1975;8:434-38. 
76 
33. Moore RD, Smith CR, Lipsky JJ, f1ellits ED, Lietmann PS. Risk 
factors for nephrotoxicity in patients treated 
glycosides. Ann Intern Med. 1984;100:352-57. 
with amino-
34. Rush DS, DiPiro JT, Record KT, Bivins BA. Diabetes: a risk factor 
in aminoglycoside nephrotoxicity. Curr Surg. 1982;39:244-47. 
35. Dahlgren JG, Anderson ET, Hewitt HL. Gentamicin blood levels: a 
guide to nephrotoxicity. Antimicrob Agents Chemother. 1975;8:58-62. 
36. Plager JE. Association of renal injury with combined cephalothin-
gentamicin therapy among patients severely ill with malignant 
disease. Cancer. 1976;37:1937-43. 
37. Smith CR, Lietman PS. Effects of furosemide on aminoglycoside-
induced nephrotoxicity and auditory toxicity in humans. Antimicrob 
Agents Chemother. 1983;23:133-37. 
38. Trollfors B. Quantitative studies on antibiotic nephrotoxicity. 
Scan J Infect Dis. 1980; suppl 21; ISSN 0300-8878. 
39. Zaske DE, Boatman JL, Solem LB, Strate RG. Increased burn patient 
survival with individualized dosages of gentamicin. Surgery. 
1982; 91: 142-49. 
40. Prince RA, Ling MH, Hepler CD, et al. Factors associ a ted with 
creatinine clearance changes following gentamicin therapy. Am J 
Hosp Pharm. 1980;37:1489-95. 
41. \Vinter fiE, Kathcher BS, Koda-Kimble MA. Gentamicin. In: Basic 
clinical pharmacokinetics. Spokane: 
1980:152-74. 
77 
Applied Therapeutics, Inc, 
42. Hull JH, Hak LJ, Koch GG, Wargin WA, Chi SL, Mattocks AM. Influence 
of range of renal function and liver disease on predictability of 
creatinine clearance. Clin Pharmacol Ther. 1981;29:516-21. 
43, Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic 
indices with thrapeutic outcome in patients receiving amino-
glycosides. Clin Pharm. 1986;5:319-24. 
78 
